Abstract
Risk of New Antidiabetic Therapies for Type 2 Diabetes’’ by Geiger et al 4 continues to demonstrate the importance of precompetitive partnering. This study examined the cardiotoxicity of drugs used to treat type 2 diabetes. Teasing out disease effects, drug effects, endpoints, and unwanted side effects is critical to the development, approval, and clinical use of medicines. We have seen the complexity of all this, demanding transparent, collaborative, and rigorous biomedical and statistical scientific approaches. Looking to the future of translational biomedical science, we will have several forward-looking papers later this year that challenge current assumptions and discuss the enormous potential that scientific advances have and will continue to provide. We anticipate an exciting year for TIRS, publishing papers that facilitate important conversations around the development of safe and effective medical products as well as increasing coordination with the Global Forum and with DIA activities to deliver to you a continuum of knowledge as we work together to foster health and well-being worldwide. —Stephen P. Spielberg, MD, PhD Editor-in-Chief, DIA Publications
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
